Clinical Trials

Women's Cardiovascular Health
Monitoring outcomes for multidisciplinary care of women with cardiac disease in pregnancy: Creating a Cardio-Obstetrics Outcomes Log (COOL)

Percutaneous Coronary Intervention (PCI)

Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II (COSIRA-II)

Cardiothoracic Surgery
EMBOLIC PROTECTION IN PATIENTS UNDERGOING HIGH RISK VALVE SURGERY

Breast Cancer

Phase 3 open label study comparing efficacy and safety of the combination of lasofoxifene and abemaciclib to the combination of fulvestrant and abemaciclib for the treatment of adults with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation

Heart Failure 
Randomized trial of ELEVATEd cardiac pacing rate for personalized treatment of Heart Failure with preserved Ejection Fraction (ELEVATEHFpEF)

Interventional Cardiology
THE MAGENTA ELEVATE™ HIGH-RISK PCI PIVOTAL STUDY

Breast Cancer 

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment

Aortic Stenosis

Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients who have Severe, Symptomatic, Aortic Stenosis Requiring Aortic Valve Replacement

Valvular Diseases

Explanted Heart Valve Registry

Heart Failure 
A randomized, double-blind, placebo-controlled pragmatic study to evaluate FINerenone on clinicAL effIcacy and safeTY in patients with Heart Failure and reduced ejection fraction who are intolerant of or not eligible for treatment with steroidal mineralocorticoid receptor antagonists

Lung Cancer

A Multicenter Randomized Trial of EBUS-TBNA Versus Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

Palbociclib and Cetuximab versus Cetuximab Monotherapy for Patients with CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial

Women's Cardiovascular Health

Heart Outcomes in Pregnancy Expectations (HOPE) for Mom and Baby

Breast Cancer 
A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations

Women's Cardiovascular Health
iSCAD Registry

Breast Cancer
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

Breast Cancer
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy

Hepatocellular Carcinoma (HCC)

A Phase II, Open-Label, Multicohort, Multicenter Study in Patients with Hepatocellular Carcinoma and Child-Pugh B Cirrhosis

Amyloidosis

A Non-interventional, Prospective, Multi-country Study Collecting Realworld Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis

Cardiometabolic

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

Breast Cancer 
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Breast Cancer

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination with Pembrolizumab as Neoadjuvant Therapy for Triple-Negative

Breast Cancer 

De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Women's Cardiovascular Health 
Peripartum Hypertension and Cardiac Assessment of Remodeling Evaluation (P-CARE)

Atrial Fibrillation

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG